Fusion protein comprising thyrotropin receptor variants and use thereof
US11479596B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jul 24, 2019 |
| Grant date | Oct 25, 2022 |
| Priority date | — |
| Expiry date | Jul 24, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.